• Merck and Moderna reported positive Phase 3 INTerpath-001 results for investigational intismeran autogene combined with Keytruda in completely resected stage IIB-IV melanoma.
• The combination significantly reduced recurrence or death and distant metastasis or death compared with Keytruda alone.
• Results will be presented for the first time at the ESMO Congress 2026 Presidential Symposium.
• No new safety signals emerged; overall survival data remain immature, with a favorable trend observed.
• The partners are engaging with regulatory authorities based on the findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261022568161) on October 22, 2026, and is solely responsible for the information contained therein.